SG11201908911QA - Modified mri contrast agents and uses thereof - Google Patents
Modified mri contrast agents and uses thereofInfo
- Publication number
- SG11201908911QA SG11201908911QA SG11201908911QA SG11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- san diego
- contrast agents
- mri contrast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT o n ono o onno (10) International Publication Number WO 2018/200615 A2 (51) International Patent Classification: A61K 49/10 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/029271 (22) International Filing Date: 25 April 2018 (25.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,159 27 April 2017 (27.04.2017) US (71) Applicants: THE REGENTS OF THE UNIVERSI- TY OF CALIFORNIA [US/US]; 1111 Franklin Street, 5th Floor, Oakland, California 94607 (US). VY- BYL HOLDINGS, INC. [US/US]; 2501 Davey Road, Woodridge, Illinois 60517 (US). (72) Inventors: LEGUYADER, Clare L. M.; 10300 N. Tor- rey Pines Rd., San Diego, California 92037 (US). GIAN- NESCHI, Nathan C.; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). CALLMANN, Cassandra E.; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). THOMPSON, Matthew P.; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). DITRI, Treffly; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). BERTIN, Paul A.; 2501 Davey Rd., Woodridge, Illi- nois 60517 (US). (74) Agent: DAILEY, Robert S.; Kilpatrick Townsend & Stockton LLP, 1001 W. 4th St., Winston Salem, North Car- olina 27101 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) = (54) Title: MODIFIED MRI CONTRAST AGENTS AND USES THEREOF N O O 00 O O FIG. 1 (57) : The present disclosure generally provides compounds useful as MRI contrast agents. In some aspects, the disclosure provides MRI contrast agents that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified MRI contrast agents and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762491159P | 2017-04-27 | 2017-04-27 | |
PCT/US2018/029271 WO2018200615A2 (en) | 2017-04-27 | 2018-04-25 | Modified mri contrast agents and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908911QA true SG11201908911QA (en) | 2019-11-28 |
Family
ID=63920047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908911Q SG11201908911QA (en) | 2017-04-27 | 2018-04-25 | Modified mri contrast agents and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200046859A1 (en) |
EP (1) | EP3615088A4 (en) |
JP (1) | JP2020517584A (en) |
KR (1) | KR20190135500A (en) |
CN (1) | CN110582306A (en) |
AU (1) | AU2018258345A1 (en) |
CA (1) | CA3057976A1 (en) |
SG (1) | SG11201908911QA (en) |
WO (1) | WO2018200615A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10023581B2 (en) * | 2015-09-22 | 2018-07-17 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4011684A1 (en) * | 1990-04-06 | 1991-10-10 | Schering Ag | DTPA MONOAMIDES, PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF |
JP3404787B2 (en) * | 1993-03-12 | 2003-05-12 | 三菱ウェルファーマ株式会社 | Novel diethylenetriaminepentaacetic acid derivative, complex compound of the derivative with a metal atom, and diagnostic agent containing the complex compound |
PT907379E (en) * | 1996-04-01 | 2004-09-30 | Epix Medical Inc | BIOACTIVATED CONTRACT AGENTS FOR DIAGNOSTIC IMAGIOLOGY |
DE19652387A1 (en) * | 1996-12-04 | 1998-06-10 | Schering Ag | Macrocyclic metal complex carboxylic acids, their use and processes for their preparation |
WO2002080757A2 (en) * | 2001-04-04 | 2002-10-17 | Metaprobe, Inc. | Novel functional agents for magnetic resonance imaging |
EP1864968A4 (en) * | 2005-03-09 | 2011-04-27 | Japan Science & Tech Agency | Complex compound and mri probe made of same |
WO2008144728A1 (en) * | 2007-05-21 | 2008-11-27 | Bracco Imaging S.P.A. | Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications |
-
2018
- 2018-04-25 SG SG11201908911Q patent/SG11201908911QA/en unknown
- 2018-04-25 KR KR1020197031523A patent/KR20190135500A/en not_active Application Discontinuation
- 2018-04-25 CA CA3057976A patent/CA3057976A1/en not_active Abandoned
- 2018-04-25 US US16/492,660 patent/US20200046859A1/en not_active Abandoned
- 2018-04-25 CN CN201880027317.0A patent/CN110582306A/en active Pending
- 2018-04-25 EP EP18791343.9A patent/EP3615088A4/en not_active Withdrawn
- 2018-04-25 AU AU2018258345A patent/AU2018258345A1/en not_active Abandoned
- 2018-04-25 JP JP2019553045A patent/JP2020517584A/en active Pending
- 2018-04-25 WO PCT/US2018/029271 patent/WO2018200615A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3615088A4 (en) | 2021-01-27 |
JP2020517584A (en) | 2020-06-18 |
US20200046859A1 (en) | 2020-02-13 |
AU2018258345A1 (en) | 2019-10-17 |
CA3057976A1 (en) | 2018-11-01 |
WO2018200615A2 (en) | 2018-11-01 |
WO2018200615A3 (en) | 2019-01-10 |
EP3615088A2 (en) | 2020-03-04 |
CN110582306A (en) | 2019-12-17 |
KR20190135500A (en) | 2019-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201809082WA (en) | Nlrp3 modulators | |
SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807025SA (en) | Crispr/cas systems for c-1 fixing bacteria | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201811643TA (en) | Compounds and methods for modulating rna function | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201804412SA (en) | Dimeric contrast agents | |
SG11201906973TA (en) | Multiple transgene recombinant adenovirus | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |